NJ State Employees Deferred Compensation Plan’s Palvella Therapeutics PVLA Stock Holding History

NJ State Employees Deferred Compensation Plan’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-375	Closed	-$5.5K	–	485
2024 Q1	$5.5K	Hold	375	–	–	﹤0.01%	480
2023 Q4	$5.46K	Hold	375	–	–	﹤0.01%	483
2023 Q3	$8.94K	Hold	375	–	–	﹤0.01%	482
2023 Q2	$4.96K	Hold	375	–	–	﹤0.01%	487
2023 Q1	$29.3K	Hold	375	–	–	﹤0.01%	488
2022 Q4	$31.2K	Hold	375	–	–	0.01%	477
2022 Q3	$35K	Hold	375	–	–	0.01%	471
2022 Q2	$56K	Hold	375	–	–	0.01%	465
2022 Q1	$91K	Hold	375	–	–	0.01%	485
2021 Q4	$113K	Hold	375	–	–	0.01%	488
2021 Q3	$155K	Hold	375	–	–	0.02%	481
2021 Q2	$115K	Hold	375	–	–	0.02%	505
2021 Q1	$77K	Hold	375	–	–	0.01%	508
2020 Q4	$75K	Hold	375	–	–	0.01%	494
2020 Q3	$62K	Hold	375	–	–	0.01%	475
2020 Q2	$93K	Hold	375	–	–	0.02%	468
2020 Q1	$68K	Hold	375	–	–	0.02%	453
2019 Q4	$109K	Hold	375	–	–	0.02%	506
2019 Q3	$102K	Buy	+375	New	+$145K	0.02%	510

Other funds holding PVLA

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

NJ State Employees Deferred Compensation Plan's PVLA Position: Q2 2024 in Review

NJ State Employees Deferred Compensation Plan sold out of Palvella Therapeutics (PVLA) in Q2 2024, closing a stake of 375 shares — an estimated $5.5K sold.

NJ State Employees Deferred Compensation Plan first reported a position in PVLA in Q3 2019 and held it in 19 quarters. The position peaked at $155K in Q3 2021. 21 funds tracked by Wall St. Rank hold PVLA as of Q2 2024.

NJ State Employees Deferred Compensation Plan reported no remaining Palvella Therapeutics position as of Q2 2024 after selling out during the quarter.
NJ State Employees Deferred Compensation Plan sold 375 Palvella Therapeutics shares in Q2 2024, an estimated $5.5K.
NJ State Employees Deferred Compensation Plan first reported a position in Palvella Therapeutics in Q3 2019 and held it in 19 quarters.
NJ State Employees Deferred Compensation Plan's Palvella Therapeutics position peaked at $155K in Q3 2021.
21 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2024.

Based on NJ State Employees Deferred Compensation Plan's 13F filing for Q2 2024, filed 6 Aug 2024.